NasdaqGS:IREN
NasdaqGS:IRENSoftware

Should IREN’s US$9.7 Billion Microsoft AI Cloud Deal Require Action From IREN (IREN) Investors?

In recent weeks, IREN secured a US$9.70 billion, five-year AI cloud infrastructure deal with Microsoft and attracted multiple analyst upgrades highlighting its expanding data center and GPU footprint. Although the Microsoft agreement underpins a multiyear AI infrastructure buildout, IREN currently generates limited AI cloud revenue, meaning meaningful monetization may take time to emerge. Next, we’ll explore how the Microsoft AI cloud contract’s scale and long buildout horizon shape IREN’s...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead’s Yeztugo Approval Highlights HIV Growth And Acquisition-Fueled Upside

Gilead Sciences (NasdaqGS:GILD) received FDA approval for Yeztugo, a twice-yearly injectable for HIV prevention. The company has started the commercial rollout of Yeztugo, adding a new product to its HIV prevention portfolio. Leadership reiterated a focus on value-creating bolt-on acquisitions to supplement Gilead’s existing pipeline. For investors watching Gilead Sciences, the FDA approval and launch of Yeztugo puts fresh attention on the company’s HIV franchise. Gilead has long been...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

Is eToro's (ETOR) Interactive Earnings Webcast Deepening Transparency or Managing the Investment Narrative?

eToro Group Ltd. has announced it will release its fourth quarter and full year 2025 results before the market opens on February 17, 2026, followed by an investor webcast including a Q&A session with management. This format, which invites the most-upvoted questions from shareholders and analysts, highlights an emphasis on direct investor engagement and transparency around upcoming financial disclosures. Next, we’ll examine how the upcoming earnings release and interactive investor webcast...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Amylyx Pharmaceuticals (AMLX) Valuation After AMX0318 Rare Disease Pipeline Update

Amylyx Pharmaceuticals (AMLX) has drawn fresh attention after selecting AMX0318, a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases, as its latest development candidate following extensive preclinical work. See our latest analysis for Amylyx Pharmaceuticals. The AMX0318 update comes after a sharp swing in sentiment, with a 1-day share price return of 15.73% and a 7-day share price return of 31.35% at a last close of $16.55. Over the past year, the...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

Is It Too Late To Consider CoreWeave (CRWV) After Recent AI Infrastructure Hype?

If you are looking at CoreWeave and wondering whether the recent excitement is already priced in, this article will walk through what the current market price might be implying about its value. CoreWeave shares last closed at US$95.22, with returns of 8.8% over the past 7 days, 14.7% over 30 days, and 20.0% year to date, which has put the stock firmly on many investors' watchlists. Recent headlines around CoreWeave have focused on its role in the high performance computing and AI...
NasdaqCM:CLSK
NasdaqCM:CLSKSoftware

CleanSpark Texas Expansion Targets AI Growth While Shifting Beyond Bitcoin Mining

CleanSpark (NasdaqCM:CLSK) has agreed to acquire a large tract of land in Brazoria County, Texas, to support new power infrastructure. The site is intended to provide substantial power capacity for artificial intelligence and high performance computing customers, alongside Bitcoin mining. The transaction marks a shift in CleanSpark's business focus toward broader data center infrastructure in a key Texas power region. CleanSpark, trading at $12.76 per share, is increasingly positioning...
NYSE:OKLO
NYSE:OKLOElectric Utilities

Oklo (OKLO) Is Down 7.4% After Meta-Backed Nuclear Campus And DOE Isotope Deal - What's Changed

In early January 2026, Oklo announced a partnership with Meta to advance a 1.2 GW nuclear power campus in Pike County, Ohio, alongside a separate U.S. Department of Energy agreement to build a radioisotope pilot facility under the Reactor Pilot Program. Together, these deals position Oklo at the junction of clean data center power and domestic medical isotope production, expanding its potential customer base beyond utilities. Next, we’ll examine how Meta’s prepayment-backed Ohio project...
NYSE:AL
NYSE:ALTrade Distributors

Is It Too Late To Consider Air Lease (AL) After A 38% One Year Rally?

Wondering if Air Lease is still good value at around US$64, or if the easy gains are already gone? This article will help you size up the stock through a clear valuation lens. Air Lease shares recently closed at US$64.33, with returns of 0.0% over 7 days, 0.3% over 30 days, 0.3% year to date, 37.9% over 1 year, 54.0% over 3 years, and 67.7% over 5 years. These figures may catch the eye of investors tracking longer term moves. Recent news around global air travel demand, fleet expansion plans...
NasdaqGS:AAL
NasdaqGS:AALAirlines

Assessing American Airlines Group (AAL) Valuation After Recent Mixed Share Price Performance

What American Airlines Group (AAL) investors may be watching now American Airlines Group (AAL) is back in focus for investors as its shares recently closed at $14.77, with returns under pressure this month but higher over the past 3 months. Given that mixed share performance, the company reports annual revenue of $54.3b and net income of $602m, providing investors with concrete figures to weigh against its current market valuation. See our latest analysis for American Airlines Group. For...
NYSE:ADM
NYSE:ADMFood

Assessing Archer-Daniels-Midland (ADM) Valuation After Erlanger Capacity Expansion Investment

Why Archer-Daniels-Midland (ADM) is in focus today Archer-Daniels-Midland (ADM) is back on investors’ radar after announcing a $26 million investment in its Erlanger campus to expand production capacity and improve efficiency for reformulated food and beverage products. The project targets naturally derived color and flavor solutions that align with cleaner label and healthier ingredient trends. It also comes on top of a previously planned $15 million expansion for 2025 in Northern...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Lucid’s Saudi Expansion Raises Questions On Funding, Cash Runway And Value

Lucid Group is preparing to begin full scale electric vehicle manufacturing in Saudi Arabia, moving beyond limited assembly activity. The Saudi facility marks the company’s first major production hub outside the United States and deepens its ties with Saudi Arabia's Public Investment Fund. This step comes while Lucid continues to rely on external funding and works through ongoing financial pressures. For investors watching NasdaqGS:LCID, this manufacturing move lands after a difficult...
NasdaqGS:SNPS
NasdaqGS:SNPSSoftware

Synopsys Weighs Nvidia AI Deal And Ansys Buyout Against Rich Valuation

Synopsys (NasdaqGS:SNPS) has secured a multi year, multi billion dollar partnership and investment from Nvidia to focus on AI driven design engineering. The company recently closed a $35b acquisition of Ansys, expanding its reach into system engineering and simulation tools. These developments build on Synopsys’s push into AI enabled EDA and system design products for chipmakers and complex hardware systems. With a current share price of $510.97, Synopsys sits at the center of attention for...
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Exelixis Targets High-Risk Colorectal Cancer As Valuation Looks Undemanding

Exelixis (NasdaqGS:EXEL) announced a new collaboration with Natera to launch STELLAR-316, a randomized phase 3 trial of zanzalintinib in stage II/III colorectal cancer. The study focuses on patients with minimal residual disease positive status, a high risk group without approved targeted therapies. Natera's circulating tumor DNA platform will be used to monitor treatment response and disease status in the trial. With shares at $43.78 and a 1 year return of 20.2%, Exelixis enters this...
NYSE:OSCR
NYSE:OSCRInsurance

Oscar Health Faces Full Exit By Blue Square As Price Nears Target

Blue Square Asset Management has disclosed the complete sale of its stake in Oscar Health (NYSE:OSCR). The transaction removes one institutional holder from the shareholder base of Oscar Health. The move is drawing attention because it was not tied to new earnings guidance or a formal company announcement. Oscar Health, listed as NYSE:OSCR, operates as a technology focused health insurer and aims to blend digital tools with traditional health plans. The company operates in a sector where...
NYSE:ITW
NYSE:ITWMachinery

Assessing Illinois Tool Works (ITW) Valuation After Deutsche Bank Issues Catalyst Call Sell Rating

Deutsche Bank’s recent “Catalyst Call: Sell” on Illinois Tool Works (ITW) has put fresh attention on the stock, with the firm highlighting potential risks related to the upcoming earnings report and any softer guidance. See our latest analysis for Illinois Tool Works. ITW’s recent 3.4% one day share price decline and softer 7 day share price return of 0.9% come after Deutsche Bank’s cautious comments. However, the 3 year total shareholder return of 18.96% and 5 year total shareholder return...
NYSE:LHX
NYSE:LHXAerospace & Defense

Pentagon Investment And Spin Off Put L3Harris Valuation In Focus

The Pentagon plans to invest US$1b into L3Harris Technologies' solid rocket motors unit, Missile Solutions. The solid rocket motors business will be spun off as a separate, publicly traded company later this year. The agreement gives the U.S. Defense Department an ownership stake in the new entity tied to NYSE:LHX. The move marks a major restructuring of L3Harris Technologies' role in the U.S. missile supply chain. L3Harris Technologies, traded as NYSE:LHX, is a major U.S. defense...
NasdaqGS:AMD
NasdaqGS:AMDSemiconductor

AMD Partnerships And Board Addition Refocus Story On AI Ecosystem Growth

Advanced Micro Devices (NasdaqGS:AMD) has formed new partnerships focused on industry specific AI and GenAI solutions with Tata Consultancy Services. AMD is working with Autolink to apply its adaptive SoCs in intelligent vehicles and automotive AI systems. KC McClure, former Accenture CFO and Goldman Sachs board member, has joined AMD's board as an independent director. For investors watching AI and enterprise computing, AMD is involved in several important shifts. The stock trades at...
NYSE:PAG
NYSE:PAGSpecialty Retail

Is It Time To Revisit Penske Automotive Group (PAG) After Solid Long Term Returns?

If you are wondering whether Penske Automotive Group's current share price reflects its true worth, you are not alone; many investors are asking the same question. The stock recently closed at US$163.02, with a 3.1% gain year to date and a 3.2% return over the past year, while still sitting on a 50.6% 3 year and 179.6% 5 year return track record. Recent coverage around Penske has focused on its position as a large auto and commercial truck retailer and its exposure to both new and used...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

ImmunityBio Approval And Trial Updates Spark Valuation Debate For Investors

ImmunityBio (NasdaqGS:IBRX) received the world's first regulatory approval for Anktiva in metastatic non small cell lung cancer from the Saudi Food and Drug Authority. The company opened a new regional office in the Middle East to support commercial rollout and partnerships in the region. ImmunityBio reported positive clinical updates for its bladder cancer program and early results from an off the shelf CAR NK cell therapy for blood cancers. ImmunityBio comes into this news with its shares...
NYSE:MP
NYSE:MPMetals and Mining

MP Materials (MP) Is Up 7.1% After Securing US$400 Million For Rare Earth Expansion - What's Changed

Recently, MP Materials cleared a key technical resistance level around US$66 and advanced its plan to use a US$400 million U.S. government investment to expand rare earth magnet manufacturing. This combination of policy support and growing attention to domestic rare earth supply chains has drawn increased analyst interest and more optimistic ratings on the stock. Next, we’ll examine how the US$400 million government backing shapes MP Materials’ investment narrative and future rare earth...
NYSE:VOYG
NYSE:VOYGAerospace & Defense

Voyager Patent And NASA Deal Spark Questions On Undervalued Growth Potential

Voyager Technologies secured a patent for microgravity based optical crystal manufacturing, tied to planned testing on the International Space Station. The company also won a NASA contract focused on STEM workforce development for space operations. These developments connect Voyager’s space manufacturing ambitions with education and hardware programs backed by a major government agency. For investors watching NYSE:VOYG, these announcements come with the stock at a recent close of $32.87 and...
NYSE:NOW
NYSE:NOWSoftware

Is ServiceNow (NOW) Resetting After Pullback Or Offering A Fresh Valuation Opportunity

If you are wondering whether ServiceNow shares are starting to look interesting at current levels, this article walks through what the current price might imply about the company’s underlying value. The stock has seen a sharp pullback recently, with a 9.3% decline over the last 7 days, a 19.3% decline over 30 days, and a 15.0% decline year to date. However, the 3-year and 5-year returns of 41.4% and 17.8% present a different picture over longer periods. Recent news coverage around ServiceNow...
NYSE:GRC
NYSE:GRCMachinery

How Investors May Respond To Gorman-Rupp (GRC) Revenue And EPS Outperformance Versus Pump Peers

In recent years, Gorman-Rupp has delivered around 13.5% annual revenue growth, a sales backlog expanding about 12.7% annually, and earnings per share compounding at roughly 33%, signaling strong operational momentum compared with many pump-industry peers. This combination of sustained revenue expansion, growing orders, and faster earnings compounding suggests Gorman-Rupp may be steadily strengthening its competitive position within its markets. Against this backdrop of robust earnings...
NYSE:DECK
NYSE:DECKLuxury

Assessing Deckers Outdoor (DECK) Valuation After Recent Share Price Weakness

Recent performance snapshot for Deckers Outdoor Deckers Outdoor (DECK) has been under pressure recently, with the stock closing at US$97.98 and showing negative returns over the past day, week, month, past 3 months, year to date, and past year. At the same time, the company reports annual revenue of US$5.24b and net income of US$1.02b, with both revenue and net income showing positive annual growth and a multi year total return that remains positive over 3 and 5 years. See our latest analysis...